Patient characteristics (n = 438) for patients who underwent myeloablative allogeneic transplantation at the University of Michigan from January 2000 to December 2005
| Characteristic . | Value . |
|---|---|
| Median age, y (range) | 42 (0-65) |
| Conditioning, no. (%) | |
| Busulfan-based | 298 (68) |
| BCNU-based | 88 (20) |
| TBI-based | 52 (12) |
| Donor source/match, no. (%) | |
| 6/6 related | 247 (56) |
| 5/6 related | 20 (5) |
| 6/6 unrelated | 124 (28) |
| 5/6 unrelated | 47 (11) |
| Sex (donor → recipient), no. (%) | |
| Male→ male | 164 (37) |
| Female → male | 101 (23) |
| Male→ female | 107 (24) |
| Female → female | 66 (15) |
| Diagnosis, no. (%) | |
| Malignant | 415 (95) |
| Nonmalignant | 23 (5) |
| Status at transplantation, no. (%) | |
| Standard risk | 264 (61) |
| Advanced risk | 151 (34) |
| Nonmalignant | 23 (5) |
| Characteristic . | Value . |
|---|---|
| Median age, y (range) | 42 (0-65) |
| Conditioning, no. (%) | |
| Busulfan-based | 298 (68) |
| BCNU-based | 88 (20) |
| TBI-based | 52 (12) |
| Donor source/match, no. (%) | |
| 6/6 related | 247 (56) |
| 5/6 related | 20 (5) |
| 6/6 unrelated | 124 (28) |
| 5/6 unrelated | 47 (11) |
| Sex (donor → recipient), no. (%) | |
| Male→ male | 164 (37) |
| Female → male | 101 (23) |
| Male→ female | 107 (24) |
| Female → female | 66 (15) |
| Diagnosis, no. (%) | |
| Malignant | 415 (95) |
| Nonmalignant | 23 (5) |
| Status at transplantation, no. (%) | |
| Standard risk | 264 (61) |
| Advanced risk | 151 (34) |
| Nonmalignant | 23 (5) |